Zoetis Inc. announced the completion of the divestiture of its medicated feed additive (MFA) product portfolio, certain water-soluble products, and related assets to Phibro Animal Health on Thursday, October 31, 2024. This transaction is a strategic move to streamline the company's portfolio.
The divestiture aligns with Zoetis's disciplined capital allocation strategy, focusing investments on areas with the highest growth potential. These areas include vaccine, biologic, and genetic programs within the livestock sector.
Zoetis remains committed to the livestock sector, emphasizing innovation in preventatives, antibiotic alternatives, and genetics, as highlighted by this strategic portfolio shift.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.